RNA Pathobiology and Therapeutics
When a disease occurs, gene activity can change, which is reflected in variations in RNA expression levels. Additionally, through the process of splicing, a single gene can produce multiple types of RNA. The pattern of splicing may be altered by disease, and in some cases, abnormalities in splicing can be the direct cause of a disease. Focusing on RNA often provides important insights into understanding diseases.
Our laboratory explores RNA expression and its regulation to investigate what happens in disease conditions and to identify key molecules that could lead to new treatments. Moreover, RNA can also be used as a therapeutic tool. It is possible to target specific genes and inhibit their function using RNA. We are actively researching ways to utilize RNA and other nucleic acid molecules as therapeutic agents.
Members
Research Topics
-
Elucidation of RNA Metabolism Regulation in Dementia-Related Genes and Its Application to Artificial Control
We are conducting research on genes associated with Alzheimer's disease and frontotemporal dementia from the perspective of RNA metabolism regulation. Specifically, we aim to elucidate the expression control of Alzheimer's disease susceptibility genes (risk genes), including APOE, TREM2, and CD33. Furthermore, we are exploring whether artificial manipulation of these genes' functions could enable therapeutic intervention in dementia pathology.
-
Regulatory Factors Controlling the Dynamics of RNA/Protein Aggregates in Repeat Expansion Disorders
Certain genetic sequences contain repeat motifs, such as CAG, CTG, and GGGGCC, where specific nucleotide patterns are repeated. Numerous diseases have been linked to abnormal expansions of these repeats, with Huntington's disease and fragile X syndrome being well-known examples. In these disorders, RNA and/or protein aggregates accumulate within cells, contributing to disease progression.
Our research focuses on the formation and degradation of these aggregates in diseases such as myotonic dystrophy, spinocerebellar ataxia, and neuronal intranuclear inclusion disease. We aim to identify molecules that influence these processes, potentially paving the way for new therapeutic approaches.